February 28, 2018

Re:GenerationHope raises awareness and funds for the complete DiGeorge Anomaly community

January 8-10, 2018

Coinciding with the annual J.P. Morgan Healthcare Conference

October 16, 2017

Global study aims to define the natural course of Farber disease

September 5, 2017

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802

September 14-17, 2017

Enzyvant will be hosting a lunch symposium on Farber disease at the PReS congress in Athens, Greece

September 5-8, 2017

Enzyvant will present two posters and an oral presentation at the WORLD Symposium in San Diego

April 17, 2017

Enzyvant receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for RVT-802

February 28, 2017

Enzyvant is participating in rare disease day! Click below for a list of local events

February 15, 2017

Enzyvant will be presenting two posters at the ICIEM conference in Rio de Janeiro, Brazil

January 9-11, 2017

Come meet us at “Rare in the Square” in Union Square, San Francisco

January 6, 2017

Enzyvant to develop a novel biologic therapy for the treatment of immunodeficiency in complete DiGeorge Syndrome

November 1, 2016

Enzyvant has announced the appointment of Dr. Alvin Shih as Chief Executive Officer

July 12, 2016

Roivant Sciences Ltd. and Plexcera Therapeutics LLC have announced the formation of Enzyvant Ltd.